The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

A Harrisburg grandfather bikes thousands of miles a year to fight against his multiple myeloma cancer. CBS 21 sat down with ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...